{Reference Type}: Journal Article
{Title}: Repurposing approved protein kinase inhibitors as potent anti-leishmanials targeting Leishmania MAP kinases.
{Author}: Bhattacharjee A;Bagchi A;Sarkar S;Bawali S;Bhattacharya A;Biswas A;
{Journal}: Life Sci
{Volume}: 351
{Issue}: 0
{Year}: 2024 Aug 15
{Factor}: 6.78
{DOI}: 10.1016/j.lfs.2024.122844
{Abstract}: <B>OBJECTIVE: </B>Leishmaniasis, caused by the protozoan parasite poses a significant health burden globally. With a very few specific drugs, increased drug resistance it is important to look for drug repurposing along with the identification of pre-clinical candidates against visceral leishmaniasis. This study aims to identify potential drug candidates against visceral leishmaniasis by targeting leishmanial MAP kinases and screening FDA approved protein kinase inhibitors.<BR><B>METHODS: </B>MAP kinases were identified from the Leishmania genome. 12 FDA approved protein kinase inhibitors were screened against Leishmania MAP kinases. Binding affinity, ADME and toxicity of identified drug candidates were profiled. The anti-proliferative effects and mechanism of action were assessed in Leishmania, including changes in cell morphology, flagellar length, cell cycle progression, reactive oxygen species (ROS) generation, and intra-macrophage parasitic burden.<BR><B>RESULTS: </B>23 MAP kinases were identified from the Leishmania genome. Sorafenib and imatinib emerged as repurposable drug candidates and demonstrated excellent anti-proliferative effects in Leishmania. Treatment with these inhibitors resulted in significant changes in cell morphology, flagellar length, and cell cycle arrest. Furthermore, sorafenib and imatinib promoted ROS generation and reduced intra-macrophage parasitic burden, and elicited anti-leishmanial activity in in vivo experimental VL models.<BR><B>CONCLUSIONS: </B>Collectively, these results imply involvement of MAP kinases in infectivity and survival of the parasite and can pave the avenue for repurposing sorafenib and imatinib as anti-leishmanial agents. These findings contribute to the exploration of new treatment options for visceral leishmaniasis, particularly in the context of emerging drug resistance.